A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Seagen Inc.
Pfizer
Genmab
Actuate Therapeutics Inc.
Revolution Medicines, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Pfizer
Neonc Technologies, Inc.
AstraZeneca
Eli Lilly and Company
Tesaro, Inc.
Eli Lilly and Company
Toray Industries, Inc
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.
Cantargia AB
Nektar Therapeutics
Incyte Corporation
Gilead Sciences